Nature Search

Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells

Interleukin-2 (IL-2) is a T-cell proliferating factor used for cancer immunotherapy. Here, the authors develop a long-lived variant of IL-2 that, mutated in its binding domain, drives a much more potent tumour regression by depleting CD25⁺ CD4⁺regulatory T-cells via targeting them for phagocytosis.

Rodrigo Vazquez-Lombardi
Claudia Loetsch
Daniel Christ
ResearchOpen Access12 May 2017
Nature Communications

Volume: 8, P: 1-12
Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies

The antitumour activity of bispecific antibodies in immunocompromised hosts can be potentiated via allogeneic T cells engineered with a T-cell receptor that decouples antigen-mediated T-cell activation from T-cell cytotoxicity.

Edo Kapetanovic
Cédric R. Weber
Sai T. Reddy
ResearchOpen Access25 Sept 2024
Nature Biomedical Engineering

Volume: 8, P: 1665-1681
Advances in antibody-based therapy in oncology

In this review article, Christ and colleagues discuss the recent developments in antibody-based cancer therapies.

Sacha Zinn
Rodrigo Vazquez-Lombardi
Daniel Christ
Reviews20 Feb 2023
Nature Cancer

Volume: 4, P: 165-180
Transient expression of human antibodies in mammalian cells

Mammalian cells are powerful expression systems for producing glycosylated recombinant antibody preparations with minimal endotoxin contamination. This protocol describes procedures for antibody design, expression, purification and characterization.

Rodrigo Vazquez-Lombardi
Damien Nevoltris
Daniel Christ
Protocols14 Dec 2017
Nature Protocols

Volume: 13, P: 99-117

Quick links

Search

Filter By:

Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells

Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies

Advances in antibody-based therapy in oncology

Transient expression of human antibodies in mammalian cells

Search

Quick links